FDA analysis: Drug prices plunge with generics competition

04/4/2006 | NYTimes.com

Competition from generics substantially reduces the prices of prescription drugs, according to an analysis by the FDA. A single challenger to a branded drug typically sells for 94% of its rival's price, but when two generics are on the market the average price drops to 52% of the name-brand's version. Prices continue to decline with even more competition, although at a slower pace, the analysis found.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC